• Ofloxacin packaged and labeled.

click on thumbnail to zoom
SKU: O001

Size  
Quantity:
  Click 'Bulk Order' for 10 or more
Price: make selection(s)
Description

Ofloxacin is a synthetic, broad-spectrum, second-generation fluoroquinolone antibiotic.  It is an analog of nalidixic acid.  Ofloxacin inhibits the  supercoiling activity of bacterial DNA gyrase, halting DNA replication.  Ofloaxacin was developed by Daiichi Seiyaku to be resistant to metabolic oxidation in the liver.  It is used to combat organisms causing urinary tract and respiratory infections.

    CAS Number

    82419-36-1

    Molecular Formula

    C18H20FN3O4

    Molecular Weight

    361.37

    Mechanism of Action

    Ofloxacin is a Cytochrome P-450 inhibitor and DNA Topoisomerase II inhibitor.  Fluoroquinolone antibiotics target bacterial DNA gyrase, an enzyme which reduces DNA strain during replication. Because DNA gyrase is required during DNA replication, subsequent DNA synthesis and ultimately cell division is inhibited.

    Storage Conditions

    2-8°C

    Tariff Code

    2934.99.3000

    Spectrum

    Ofloxacin is a broad-spectrum antibiotic targeting a wide range of Gram-positive and Gram-negative organisms.

Applications

    Cancer Applications

    Oflaxacin had an inhibitory effect on the proliferation of transitional cell carcinoma cell lines at high concentrations (>200 μg/ml).  The effect may be related to impairment of telomerase activity by some unknown mechanism (Yamakuchi M et al, 1997).

    Ofloxacin inhibited proliferation and DNA synthesis of these 3 human TCC lines (CCSUP, T24, and J82 ) in vitro. Inhibition occurred in a concentration- and time-dependent manner. Inhibition of proliferation and DNA synthesis were assessed via MTT and tritiated thymidine assays (Seay, 1996).

    Microbiology Applications

    Ofloxacin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.  Representative MIC values include:

      • Haemophilus influenzae  0.016 µg/mL – 0.063 µg/mL
      • Escherichia coli  0.063 µg/mL – 0.125 µg/mL
      • For a complete list of Ofloxacin MIC values, click here.

Specifications

    Form

    Powder

    Appearance

    White crystalline powder

    Source

    Synthetic

    Impurity Profile

    Impurity A| (RS)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid (FPA) ; Ofloxacin Difluoro Carboxylic Acid|82419-35-0|C13H9F2NO4|281.21| Impurity B| (RS)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-2,3-dihydro-7H-pyrido-[1,2,3-de]-1,4-benzoxazin-7-one|||| Impurity E| (RS)-9-Fluoro-3-methyl-7-oxo-10-(piperazin-1-yl)-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid; N-Desmethyl Ofloxacin HCl|82419-52-1|C17H18FN3O4|347.34| Impurity F| 4-[(RS)-6-Carboxy-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-10-yl]-1-methylpiperazine 1-Oxide Hydrochloride (Ofloxacin N-Oxide Acetate Salt)|104721-52-0|C20H24FN3O7|437.42| | Ofloxacin R-Isomer; (+)-(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid ;(R)-(+)-Ofloxacin ;D-Ofloxacin ; Levofloxacin R-Isome|100986-86-5|C18H20FN3O4|361.37|

    Melting Point

    250-257°C

    Optical Rotation

    -1° to +1°

    Assay

    (On Dried Basis): 98.5-101.5%

    Loss on Drying

    ≤0.2%

References

    References

    Mouton Y and Leroy O (1991)  Ofloxacin. Int. J. Antimicrob. Agents 1(2-3):57-74

    Seay TM, Peretsman SJ and DIxon PS (1996)  Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics.  J. Urol. 2:757-762  PMID 8558720

    Smith JT (1991)  Ofloxacin, a bactericidal antibacterial. Chemother. 37 (supp 1):2-13  PMID 1646700

    Wolfson JS and Hooper DC. (1985)  The Fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother 28(4): 581-586.

    Yamakuchi M, Nakata M, Kawahara K, Kawahara K, Kitajima I and Maruyama I (1997)  New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett. 119(2):213-219  PMID  9570374

Other Items In This Category